Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Thanxs for all the numbers numbers.

1. I think Rexista will have a hard time competing against Oxycontin also. 2. There is little incentive for existing Oxycontin users to switch. 3. You also have to convince doctors to prescribe your new drug over Oxycontin.

I think it will depend on the quality and financial muscles of the partner... for Pfizer or J & J... it would be a walk in the park.

1. I think it's pretty well known that Oxycontin, although prescribed as 2x a day doesn't really last 12 hours... that is what I would hammer home... assuming Rexista XR lasts a full 12 hours - which I believe it does... a well laid out chart showing that advantage would go a long way to convince both doctors and patients to switch.

2. I would price it the same as Oxycontin and offer a 25% to 30% voucher that's good for 12 months.

3. The old "never fail" I have a couple of airline tickets and a 3 day stay at this wonderful new golf resort that I can't use... wonder if you would "do me a favor" and take them off my hands!!!

I think Rexista can/will sell $60 million on the 1st year, with a $100 million expenditure, $200 million second year with $80 million expenditure, $350 million third year with $60 million expenditure, and $400 to $450 million steady state thereafter with a $40 million a year expenditure.

p.s. IPCI can/will profit from the outset... including approximately ~ $20 million in royalties the first year out.

p.s.s. - the above figures are reflections of what I think will happen once Rexista XR is accepted on the formularies.